Summit Therapeutics Share Discussion Threads

[chrisatrdg] 21/9/2017 16:07

Hi football - This RNS is significant as it (I believe) is a new investor following recent share issues.

[football] 21/9/2017 16:02

Got another holding RNS today, they seem to be like buses none for ages then to come along at once

[chrisatrdg] 21/9/2017 15:58

WORLD MUSCLE SOCIETY CONGRESS

3-7 October 2017, St Malo, France

Posters of interest involving K.Davies & Summit staff

Wednesday 4 October 2017

P.235 Circulating miRs biomarkers for therapeutic monitoring in utrophin based DMD therapy N. Ramadan; S. Guiraud; B. Edwards; S. Squire; S. Hemming; K. Davies

P.239 Identification of serum protein biomarkers for utrophin based DMD therapy
S. Guiraud; B. Edwards; S. Squire; A. Babbs; N. Shah; A. Berg; H. Chen; K. Davies

Thursday 5 October 2017

P.308 Discovery of small molecule utrophin modulators for the therapy of Duchenne muscular dystrophy

G. Wynne; A. Vuorinen; E. Emer; D. Conole; M. Chatzopoulou; S. Davies; A. Russell; S. Guiraud; S. Squire; A. Berg; B. Edwards; S. Hemming; T. Kennedy; L. Moir; K. Davies; S. Harriman; J. Tinsley; F. Wilson

P.308 PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromid

F. Muntoni; K. Maresh; K. Davies; S. Harriman; G. Layton; R. Rosskamp; A. Russell; B. Tejura; J. Tinsley

P.469 Collection of high quality muscle biopsies for use in DMD clinical trial analysis; process development and implementation

J. Tinsley; D. Frank; J. Dworzak; C. Faelan; J. Patterson-Kane; H. Wolff; F. Muntoni; PhaseOut DMD Study Group

[waterloo01] 21/9/2017 11:08

With funding out the picture for now i think it's a case of place your bets take a position and wait. Any over hang of shares should quickly clear imo

[chrisatrdg] 20/9/2017 21:45

I hope you are right football thanks for the posting.

[football] 20/9/2017 21:19

penny dropped at last?

12.69 up (3.68%)

[hugus maximus] 20/9/2017 17:09

Is it just me ... or am I the only one who didn't get an email note about the RNS explaining Lansdowne have increased their holding?

[chrisatrdg] 20/9/2017 16:39

Update on Summit Conferences

WORLD MUSCLE SOCIETY CONGRESS

3-7 October 2017, St Malo, France


ID WEEK

4-8 October 2017, San Diego, US

[luminoso] 20/9/2017 14:40

Governments need to step in and encourage them - as Jim Neill (?) said a while back.

[hugus maximus] 20/9/2017 14:25

Interesting article Chris ... yet the major pharmas seem to have no interest, as they see little profit in anti-biotics and of course that's all they are motivated by ... what a sad and bizarre world.

[chrisatrdg] 20/9/2017 13:50

Too few antibiotics in pipeline to tackle global drug-resistance crisis, WHO warns

Article includes:

'Hospital infections such as C. difficile and MRSA (methicillin-resistant Staphylococcus aureus) are also of major concern. They are a particular danger to patients who are already sick and have fragile immune systems.'

Link:

[luminoso] 20/9/2017 12:50

Recent strengthening of pound/dollar might explain some price slippage.

[luminoso] 18/9/2017 15:55

Agree, waterloo.

[waterloo01] 18/9/2017 14:05

I hope that one of the messages in the size if the raise at around 10% dilution, is that at least for the period leading up to the next major milestone (EZT), they don't need to raise again. If they didn't expect to see an upward movement in the market cap after that, they would probably have raised more now?

[phowdo] 18/9/2017 13:18

The chart is still showing a nice uptrend despite the placing.

[waterloo01] 18/9/2017 12:16

Cheers. Getting over the placing and nice to see a 31k share buy just printed.

[luminoso] 18/9/2017 11:44

Nice one, waterloo.

[waterloo01] 18/9/2017 08:53

Daily mail from Friday Eve

[luminoso] 17/9/2017 12:18

Thanks chrisatrdg.

" Drug developer Summit Therapeutics PLC (LON:SMMT) will effectively secure its financial future with a fully underwritten issue of stock that could bring in as much as US$20mln."

Which is why I do not have a problem with the price of the raising.

[chrisatrdg] 16/9/2017 13:44

As others see us:

Summit Therapeutics' US fundraiser should secure drug developer's long-term financial future
07:36 14 Sep 2017

Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor

The company is getting some traction for its story Stateside
Drug developer Summit Therapeutics PLC (LON:SMMT) will effectively secure its financial future with a fully underwritten issue of stock that could bring in as much as US$20mln.

The AIM-listed firm, which is also quoted on the NASDAQ exchange, is issuing 1.459mln new American depositary shares at US$12 each, bringing in a minimum of US$17.5mln.

A further 218,850 units are available to meet excess demand, which would take the total to US$20.1mln.

Canaccord Genuity and JMP Securities are leading the American fundraiser, while Lansdowne Partners, one of Europe’s largest hedge funds, has come in as a cornerstone investor.

US funding boost

The injection of investor cash follows news last week Summit had secured a funding package of US$62mln from US authorities to bankroll the development of its next-generation antibiotic, Ridinilazole.

READ: Summit Therapeutics soars after securing funding from US government agency

Earlier this year it received a US$22mln milestone payment from the US biotech Sarepta related the progress of Ezutromid, its treatment for Duchenne Muscular Dystrophy (DMD), a rare muscle-wasting disease that affects boys.

Ezutromid recently completed enrolment for its PhaseOut phase II clinical trial, which triggered the payment from partner Sarepta.

Study underway

The study recruited 40 patients in the US and UK and will take 48 weeks to complete.
Researchers will assess how it affects muscle structure, health and function.
Data from the half-way stage is expected in the first quarter of next year with the trial set to close in the third quarter.

Blockbuster potential

Ridinilazole, meanwhile, could be a blockbuster for the company as well as providing a breakthrough against antibiotic resistance.

READ: Summit Therapeutics antibiotic delivers encouraging clinical trial results

It is thought to be effective against multiple different strains of the difficult-to-treat infection c.difficile (CDI).
It is also believed to be superior to existing medications such as vancomycin and metronidazole.
“We believe ridinilazole can become a new, urgently needed frontline therapy for this serious infectious disease,” said chief executive Glyn Edwards said recently

[chrisatrdg] 15/9/2017 19:18

Additional shares have been taken out see press release below:

[chrisatrdg] 15/9/2017 19:04

Thanks for the post waterloo01 I must say one of the more positive publication I have read on Summit for a while & concur with the sentiment of the article.Buy on the dip is a good way of looking at it.

[waterloo01] 15/9/2017 18:19

Pretty bullish!